The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.
 
Andrew J. Armstrong
Honoraria - Astellas Scientific and Medical Affairs Inc
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Dendreon; Merck; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Agenus; Castle Biosciences; Daiichi Sankyo; Deciphera; Imaging Endpoints; Neon Therapeutics; RedHill Biopharma; Salarius Pharmaceuticals; TRACON Pharma
Research Funding - AADi (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Agenus (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Beigene (Inst); BiolineRx (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); CanBas (Inst); cantex (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); FibroGen (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genocea Biosciences (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Helix BioPharma (Inst); Hengrui Therapeutics (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Inhibrx (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Revolution Medicines (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Syndax (Inst); SynDevRx (Inst); Syros Pharmaceuticals (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); TTC Oncology (Inst); Verastem (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Melissa Andrea Reimers
No Relationships to Disclose
 
Alex Sedkov
Employment - Forma Therapeutics
Stock and Other Ownership Interests - Forma Therapeutics
 
Kate Lipford
Employment - Forma Therapeutics
Stock and Other Ownership Interests - Forma Therapeutics
 
Juliana Snavely-Merhaut
Employment - Forma Therapeutics
Stock and Other Ownership Interests - Forma Therapeutics
 
Sonia Kumar
Employment - Forma Therapeutics
Stock and Other Ownership Interests - Forma Therapeutics
 
Sylvie Mireille Guichard
Employment - Forma Therapeutics
Stock and Other Ownership Interests - Forma Therapeutics
 
Neal Shore
Honoraria - Abbvie; Amgen; Astellas Oncology; AstraZeneca; Bayer; BMSi; Boston Scientific; Clovis Oncology; Dendreon; Exact Imaging; FerGene; Foundation Medicine; GC Oncology; Invitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Pharmaceuticals; Nymox; Pfizer; Prepella; Sanofi; Sesen Bio; Tolmar
Consulting or Advisory Role - Abbvie; Amgen; Astellas Oncology; AstraZeneca; Bayer; BMSi; Boston Scientific; Clovis Oncology; Dendreon; Exact Imaging; FerGene; Foundation Medicine; GC Oncology; Invitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Pharmaceuticals; Nymox; Pfizer; Prepella; Sanofi; Sesen Bio; Tolmar
Speakers' Bureau - Astellas Oncology; AstraZeneca; Bayer; Clovis Oncology; Guardant Health; Janssen; Pfizer
Research Funding - Abbvie; Amgen; Astellas Oncology; AstraZeneca; Bayer; BMSi; Boston Scientific; Clovis Oncology; Dendreon; Exact Imaging; FerGene; Foundation Medicine; GC Oncology; Invitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Pharmaceuticals; Nymox; Pfizer; Prepella; Sanofi; Sesen Bio; Tolmar